New device achieves important regulatory milestone for eye surgery.
- The Fixoflex device is designed for use in eye surgery.
- Achieving CE Mark allows for market introduction in Europe.
- This regulatory milestone supports advancements in ocular care.
Eye PCR has announced that its Fixoflex endocapsular device has received the CE Mark, a significant regulatory achievement that allows the device to be marketed in Europe. This approval paves the way for the utilization of Fixoflex in cataract surgeries, enhancing surgical options for patients and healthcare providers alike. With the Fixoflex device, Eye PCR aims to improve outcomes for individuals undergoing eye procedures.
The CE Mark signifies that the Fixoflex endocapsular device meets the essential health and safety requirements established by European regulations. This device is designed to assist in the management of cataracts and improve the overall efficiency of eye surgeries. Eye PCR’s commitment to innovation and patient care is reflected in the development of this device, which is expected to contribute positively to the field of ophthalmology.
This milestone marks a crucial step for Eye PCR as it expands its footprint in the European market. With the Fixoflex device now available, the company aims to address the growing demand for advanced medical devices in eye surgeries. The CE Mark approval further solidifies Eye PCR’s position in the ocular care market.
